Biobot Surgical raises $15.5m to take its prostate-cancer robot to the US
What's the deal? Singapore's Biobot Surgical has raised S$20 million (about $15.5 million) in a round led by ClavystBioDealroom has a profile for this one. Try Dealroom →, the biotech investor established by Temasek.
The startup builds robotic systems for prostate cancer diagnosis and treatment. Its Mona Lisa platform pairs robotic needle guidance with MRI-ultrasound image fusion for targeted biopsies and focal ablation.
New backer ClavystBio joins existing cornerstone shareholder ZIG VenturesDealroom has a profile for this one. Try Dealroom →. The cap table also includes Astrid Hill InvestmentDealroom has a profile for this one. Try Dealroom →, KUPADealroom has a profile for this one. Try Dealroom →, PTSM Holdings, Jia Yu Capital, oncologist Ang Peng Tiam, and defence scientist Lui Pao Chuen.
Why now? The deal confirms an April 2026 report that Biobot was raising fresh capital, and it arrives as the company pushes into the US.
To do so, Biobot will partner with Silicon Valley's Fogarty Innovation to identify priority clinical segments and accelerate adoption among physicians.
Founded in 2017, the company has installed more than 80 systems worldwide, supported over 30,000 patients, and completed over 23,000 procedures across Europe and Asia-Pacific.
What could go wrong? Surgical robotics is capital-intensive and slow to scale. Selling hardware into US hospitals means navigating tough regulatory clearances and entrenched competition.
Biobot has secured five key clearances so far, but its leadership signals the harder task is changing how doctors work.
"The objective is not simply to place systems, but to build Mona Lisa into a precision intervention platform for prostate care," chief executive officer Sim Kok Hwee said.
The signal: Dealroom classifies Biobot as a breakout-stage company, and ClavystBio's mandate to commercialise Asian medtech into global markets aligns neatly with the startup's US push. The deal is a test of whether a Singapore-built precision robotics platform, already deployed across Europe and Asia-Pacific, can crack the harder American market.
Read more: DealStreetAsia
Image credit: NavyMedicine
